
About Us
The Canadian Pharmaceutical Manufacturers and Exporters Alliance (CPMEA) represents Canadian pharmaceutical manufacturers operating production facilities in Canada, making medicines for Canadian patients and export. Our members are the largest manufacturers of medicines by volume in Canada, providing innovative, generic and biosimilar pharmaceuticals, and non-prescription medications. Our purpose is to highlight the importance of local pharmaceutical development and manufacturing for public health resilience and national security. A strong Canadian-based production network is essential to reduce Canada’s vulnerability to supply disruptions and heavy dependence on imported medicines. Through engagement with stakeholders, the Alliance brings together thought leaders to build a healthy future for domestic drug production and to ensure sovereignty of supply for Canadians.
Member Companies
With a legacy spanning 50 years, Apotex is dedicated to enhancing access to affordable and innovative medicines globally. As the largest Canadian-based pharmaceutical company, Apotex's broad portfolio and unwavering dedication to healthcare professionals and patients have solidified its position as a trusted partner. Notably, Apotex exports to 75 countries worldwide, further expanding its impact and reach in the pharmaceutical industry.
Founded in Canada in 1983, Pharmascience is a leading manufacturer of generic, branded, and over-the-counter pharmaceuticals, serving markets in over 50 countries. With a commitment to quality, R&D, and community service, Pharmascience has evolved from a modest start-up to a global player in the pharmaceutical industry, employing 1,500 individuals dedicated to excellence.
Established in Quebec over 40 years ago, Laboratoire Riva is a pioneer in manufacturing generic products, driven by cutting-edge technology and an unwavering commitment to customer service and innovation. With a dedicated team, Laboratoire Riva invests in research and development to ensure partner satisfaction and community growth.
Board Members

Terry Creighton
President, Canadian Pharmaceutical Manufacturers and Exporters Alliance

David Goodman
Executive Chairman,
Pharmascience

Allan Oberman
President & CEO,
Apotex Inc.

Olivier St. Denis
President
Laboratoire Riva, & Avir Pharma Inc.
Board Members
David Goodman
Executive Chairman,
Pharmascience
Allan Oberman
President & CEO,
Apotex Inc.
Olivier St. Denis
President,
Laboratoire Riva & Avir Pharma Inc.
Terry Creighton
President,
Canadian Pharmaceutical Manufacturers and Exporters Alliance

OUR VALUES
CANADA FIRST
Canadian pharmaceutical producers play a crucial role in providing a dependable supply of medicines for Canadians, reducing our reliance on foreign sources, and averting shortages. This commitment ensures that Canadians have access to top-quality medicines that meet the highest standards manufactured locally in Canada. Domestic manufacturing capacity is a vital public health asset and a valuable national economic resource.

OUR VALUES
ACCESS
We are committed to ensuring access to essential medicines for all Canadians. Canadian domestic pharmaceutical manufacturers strive to reduce barriers to access, ultimately improving healthcare outcomes and quality of life for all Canadians. Our goal is to ensure that every patient has equitable and affordable access to the medications they need.

OUR VALUES
TRUST
Trust is at the core of everything we do. Canadian pharmaceutical producers are respected worldwide for supply reliability, product safety, and rigorous compliance with the highest global standards in pharmaceutical manufacturing. Our commitment to providing the best quality medications is unwavering. You can trust that Canada’s drug producers will be there to ensure availability, security, and quality.

OUR VALUES
ECONOMIC SUSTAINABILITY
The Canadian pharmaceutical manufacturing industry is confronting a sustainability crisis. facing challenges due to competition from global players in low-wage countries, while costs have escalated due to inflation, higher wages, and changing regulatory obligations. The COVID-19 pandemic underscored the vulnerability of our medical supply chain, highlighting the essential nature of local production, too. A strong domestic pharmaceutical manufacturing sector is critical and represents the opportunity to achieve broad-based economic gains, as well as public health security. We call on all levels of government to make Canadian pharmaceutical manufacturing a priority, recognizing its critical role in safeguarding the sovereignty of Canada’s medicines supply.